Literature DB >> 24423116

Adoptive immunotherapy for cancer or viruses.

Marcela V Maus1, Joseph A Fraietta, Bruce L Levine, Michael Kalos, Yangbing Zhao, Carl H June.   

Abstract

Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the treatment of cancer and certain chronic viral infections. The application of the principles of synthetic biology to enhance T cell function has resulted in substantial increases in clinical efficacy. The primary challenge to the field is to identify tumor-specific targets to avoid off-tumor, on-target toxicity. Given recent advances in efficacy in numerous pilot trials, the next steps in clinical development will require multicenter trials to establish adoptive immunotherapy as a mainstream technology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423116      PMCID: PMC4533835          DOI: 10.1146/annurev-immunol-032713-120136

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  199 in total

1.  Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.

Authors:  C P Broeren; G S Gray; B M Carreno; C H June
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

2.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

3.  Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.

Authors:  K Liu; S A Rosenberg
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Authors:  Marcela V Maus; Anna K Thomas; Debra G B Leonard; David Allman; Kathakali Addya; Katia Schlienger; James L Riley; Carl H June
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

5.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Authors:  E Y Woo; C S Chu; T J Goletz; K Schlienger; H Yeh; G Coukos; S C Rubin; L R Kaiser; C H June
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

6.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

Authors:  T Stanislawski; R H Voss; C Lotz; E Sadovnikova; R A Willemsen; J Kuball; T Ruppert; R L Bolhuis; C J Melief; C Huber; H J Stauss; M Theobald
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

7.  Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.

Authors:  R T Mitsuyasu; P A Anton; S G Deeks; D T Scadden; E Connick; M T Downs; A Bakker; M R Roberts; C H June; S Jalali; A A Lin; R Pennathur-Das; K M Hege
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Authors:  R E Walker; C M Bechtel; V Natarajan; M Baseler; K M Hege; J A Metcalf; R Stevens; A Hazen; R M Blaese; C C Chen; S F Leitman; J Palensky; J Wittes; R T Davey; J Falloon; M A Polis; J A Kovacs; D F Broad; B L Levine; M R Roberts; H Masur; H C Lane
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

9.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Authors:  Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

10.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

View more
  123 in total

Review 1.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

Review 2.  The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.

Authors:  Asha Purnima Veerappan Ganesan; Laurence C Eisenlohr
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

Review 3.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

4.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

5.  Automated generation of immature dendritic cells in a single-use system.

Authors:  Andrew Kozbial; Lekhana Bhandary; Bradley B Collier; Christopher S Eickhoff; Daniel F Hoft; Shashi K Murthy
Journal:  J Immunol Methods       Date:  2018-04-03       Impact factor: 2.303

Review 6.  The next steps in next-gen sequencing of cancer genomes.

Authors:  D Neil Hayes; William Y Kim
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 7.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

8.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

9.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo
Journal:  JCI Insight       Date:  2017-12-07

10.  Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory.

Authors:  Hidehito Saito; Keisuke Okita; Alfred E Chang; Fumito Ito
Journal:  Cancer Res       Date:  2016-04-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.